CNSP Valuation
CNS Pharmaceuticals Inc
$
1.300
- Overview
- Forecast
- Valuation
CNSP Relative Valuation
CNSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNSP is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for CNSP's competitors is 0.31, providing a benchmark for relative valuation. CNS Pharmaceuticals Inc Corp (CNSP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
AVGO
Broadcom Inc
230.760
USD
+0.94%
AMZN
Amazon.com Inc
206.280
USD
+0.34%
MSFT
Microsoft Corp
458.550
USD
+0.94%
META
Meta Platforms Inc
641.835
USD
+0.23%
AAPL
Apple Inc
208.740
USD
-1.19%
XOM
Exxon Mobil Corp
106.360
USD
-1.69%
WMT
Walmart Inc
98.100
USD
-0.14%
TSLA
Tesla Inc
339.915
USD
-2.88%
NVDA
NVIDIA Corp
135.370
USD
-0.02%
ORCL
Oracle Corp
161.640
USD
+0.72%
FAQ
Is CNS Pharmaceuticals Inc (CNSP) currently overvalued or undervalued?
CNS Pharmaceuticals Inc (CNSP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of CNS Pharmaceuticals Inc (CNSP) is between to according to relative valuation methord.
What is CNS Pharmaceuticals Inc (CNSP) fair value?
How does CNSP's valuation metrics compare to the industry average?
What is the current P/B ratio for CNS Pharmaceuticals Inc (CNSP) as of May 19 2025?
What is the current FCF Yield for CNS Pharmaceuticals Inc (CNSP) as of May 19 2025?
What is the current Forward P/E ratio for CNS Pharmaceuticals Inc (CNSP) as of May 19 2025?